NCT00082537View on ClinicalTrials.gov

MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
NeutropeniaFever
Interventions
DRUG

caspofungin acetate

Duration of Treatment: 28-90 days

DRUG

Comparator: AmBisome

Duration of Treatment: 28-90 days

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00082537 - MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044) | Biotech Hunter | Biotech Hunter